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Abstract Magnetic resonance imaging and multidetector
computed tomography are new imaging methods that have
much to offer clinicians caring for patients with dilated
cardiomyopathy.Inthisarticlewebrieflydescribetheclinical,
pathophysiological and histological aspects of dilated cardio-
myopathy. Then we discuss in detail the use of both imaging
methods for measurement of chamber size, global and
regional function, for myocardial tissue characterisation,
including myocardial viability assessment, and determination
of arrhythmogenic substrate, and their emerging role in
cardiac resynchronisation therapy.
Keywords Dilated cardiomyopathy.Magnetic resonance
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Introduction
The term “cardiomyopathy” identifies a heterogeneous
group of cardiac diseases characterised by direct myocar-
dial involvement leading to impaired cardiac function.
Since the term was introduced by Harvey and Brigden in
the 1960s, substantial progress has been made, in terms of
understanding the pathophysiological substrate, underlying
causes and peculiarities, and most importantly, in defining a
classification system for cardiomyopathies. Primary cardio-
myopathies include those with genetic, acquired or mixed
causes, and refer to a disease that is predominantly limited
to the myocardium, whereas secondary cardiomyopathies
are characterised by myocardial involvement that is part of
a generalised or diffuse systemic disorder. In addition,
several cardiovascular diseases not regarded as cardiomy-
opathies may also affect the myocardium, causing systolic
or diastolic dysfunction and hampering differentiation from
heart muscle diseases [1]. Although with the current arsenal
of diagnostic imaging tools, the diagnosis of cardiomyop-
athies has been facilitated, in many cases the correct
diagnosis remains challenging and sometimes elusive.
Nevertheless, these techniques have significantly contribut-
ed towards an increased awareness of cardiomyopathies
among clinicians, and they have an increasing impact on
patient management and risk stratification. Transthoracic
echocardiography is currently the first-line imaging tech-
nique for the diagnosis, evaluation and decision-making in
cardiomyopathy patients. In the last decade, magnetic
resonance imaging (MRI) and, to a lesser extent, multi-
detector (or multirow) computed tomography (MDCT)
have become increasingly important in the diagnosis of
cardiomyopathies. In particular, the comprehensive ap-
proach of MRI, including non-invasive tissue character-
isation, makes it indispensable in the work-up of many
cardiomyopathies.
Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is the most common
cardiomyopathy worldwide with a prevalence of 40–50
cases per 100,000. DCM is currently classified as primary
(genetic, acquired or mixed), secondary (e.g. infiltrative or
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DOI 10.1007/s13244-011-0101-8autoimmune) and idiopathic. Genetic inheritance is likely to
play a role in the development of the disease in 20-35% of
patients, but also acquired conditions like metabolic
abnormalities, inflammatory and infectious processes, neu-
romuscular diseases and a large variety of cardiotoxic
agents (chemotherapeutic agents, alcohol, illicit drugs) can
lead to DCM [1–4]. Independently of the underlying cause,
DCM is characterised by an increase in diameter and
volume of the left or both ventricles, leading to progressive
dilatation and impaired systolic function that is not
secondary to or cannot be exclusively justified by abnormal
loading conditions (e.g. valve disease, hypertension) or by
the concomitant coronary artery disease (CAD) (Figs. 1 and
2) (Movie 1)[ 1–3]. Thus, the term DCM represents a final
common pathway that is the end result of myocardial
damage.
Pathophysiological and histological aspects
Independently of the underlying cause, DCM is character-
ised by an increase in ventricular chamber size. As
demonstrated by the Frank-Starling mechanism, this serves
as a first compensatory step aiming to maintain an
appropriate stroke volume. However, above a critical
sarcomere stretch, the efficiency of interaction between
actin and myosine filaments decreases, resulting in impair-
ment of stroke volume. Myocardial fibre elongation
increases the ventricular radius, causing eccentric ventric-
ular hypertrophy, with decreased wall thickness to chamber
diameter ratio and increased ventricular sphericity. Accord-
ing to the Laplace law, these changes increase significantly
myocardial wall stress with increased oxygen demand and
subsequent worsening of the left ventricular (LV) systolic
performance [5]. The main histological features of DCM
are myocyte elongation, myocardial apoptosis and hypertro-
phy of the remaining myocytes [6]. Additionally, there is an
excessive collagen deposition and decreased capillary density,
with both reactive (interstitial and perivascular) and reparative
(replacement) patterns of fibrosis [7, 8]. Myocardial fibrosis is
considered the result of damage due to microvascular
ischaemia and myocardial wall inflammation. The cellular
and extracellular changes result in a normal, thinned or
slightly thickened myocardial wall (Fig. 1).
Clinical manifestation
The clinical presentation of DCM is variable, but the
severity of symptoms is usually related to the grade of
systolic impairment. Although patients can be asymptom-
atic, especially in the early phases of the disease, most of
them have symptoms of left heart failure, such as dyspnoea
and effort-related fatigue. In some cases, severe LV systolic
dysfunction and advanced heart failure symptoms are
present in patients with normal or mildly dilated ventricles
(less than 10-15% above normal range), i.e. mildly dilated
forms of DCM [1]. Sudden cardiac death can be the first
clinical evidence of DCM and it is due to sustained
ventricular tachycardia and ventricular fibrillation. It is
deemed that the more severe the systolic dysfunction and
the degree of replacement fibrosis, the larger the arrhyth-
mogenic substrate that can provoke malignant arrhythmias.
Other potentially life-threatening manifestations of DCM
are non-sustained ventricular arrhythmias, conduction ab-
normalities, syncope and embolic events. As the disease
progresses, right heart failure may develop, and it is
considered an aggravating factor (Fig. 3)[ 9, 10]. Thus,
right ventricular (RV) dilatation and dysfunction can be
present, but are not requirements for the diagnosis of DCM.
Fig. 1 Extreme form of dilated cardiomyopathy in a 63-year-old man.
SSFP cine MRI in a four-chamber view at end-diastole (left), mid-
systole (mid), and late-systole (right) (see Movie 1). The left ventricle
(LV) end-diastolic volume is 877 ml with an ejection fraction of 12%.
The right ventricle (RV) end-diastolic volume is 248 ml with an
ejection fraction of 42%. Presence of an important mitral regurgitation
secondary to dilatation of the mitral valve ring. The regurgitation is
visible during systole (white arrowheads in the middle and right
panels). Velocity-encoded MRI shows a regurgitant volume of 45 ml
through the mitral valve
454 Insights Imaging (2011) 2:453–469Fig. 2 LV volume overload due
to aortic regurgitation in 21-
year-old man with Marfan’s
disease. Diastolic SSFP cine
MR image in a three-chamber
view (a) and LV outflow tract
view (b). Velocity-encoded cine
MRI just below the level of the
aortic valve at systole (c) and
diastole (d). Dilated LV with an
end-diastolic volume of 500 ml,
a stroke volume of 255 ml and
an ejection fraction of 51%.
Cine MRI (a, b) shows
important aortic regurgitant jet
(arrows). Velocity-encoded cine
MRI shows non-closure of the
aortic valve leaflets during
diastole (d) with a regurgitant
fraction of 43%
Fig. 3 Extreme form of dilated
cardiomyopathy in an 11-year-
old girl involving both
ventricles, and clinically
presenting with severe
symptoms of heart failure. SSFP
cine MR image in the axial
plane at end-diastole (a) and
end-systole (b). Late gadolinium
enhancement (LGE) MRI in the
midventricular short-axis plane
(c) and axial plane (d). Note the
important dilatation of both
ventricles, i.e. LV end-diastolic
volume of 324 ml, RV
end-diastolic volume of 520 ml
with an ejection fraction of 9%
and 7% for the LV and RV
respectively. LGE MRI shows
diffuse strong subepicardial
enhancement in the LV (white
arrows in c, d), along the
subendocardium of the RV
(black arrows)( d), and of the
RV free wall (white arrowheads)
(d). Unfortunately the patient
died while on the waiting list for
a cardiac transplant
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The requirements for appropriate imaging in cardiomyopa-
thiesnowadaysexceedthepurediagnosticobjective,whereby
assessment of the more intricate aspects, such as depiction of
underlying aetiology, risk assessment, therapy planning and
determination of prognosis, are becoming increasingly im-
portant. MRI, because of its non-invasive nature, its excellent
spatial, contrast and temporal resolution, and capability for
tissue characterisation, has become a well-validated and
widely accepted technique for studying DCM patients. In
addition, the constant improvement in MDCT technology,
especially since the introduction of the 64-rowsystems, offers
reliable imaging of the heart and coronaries, offering new, yet
incompletely explored approaches to studying DCM patients
(Fig. 4). Several studies have independently shown that
MDCT is highly appropriate for excluding coronary artery
disease, yielding excellent negative predictive values [11–
14]. Moreover this technique enables the characterisation of
the coronary venous system, which may be of great help in
the planning of cardiac resynchronisation therapy (CRT). In
patients with contra-indications for MRI, such as those with
permanent cardiac implantable devices, MDCT is an
interesting diagnostic alternative.
Cine MRI is nowadays considered the reference tech-
nique for accurately measuring cardiac chamber size,
ventricular function and myocardial mass (Figs. 1 and 3)
[10, 15–18]. Moreover, derived parameters, such as
Fig. 4 Ventricular assist device
in a 62-year-old man with end-
stage DCM. MDCT showing
four axial slices through the
heart and upper thorax (a-d),
volume-rendered view (e). Note
the presence of a severely
dilated LV with thin walls. The
LV is shortcut by the assist
device between the left atrium
and right subclavian artery
(arrow in b, d). The course of
the ventricular assist device can
be well appreciated on the
volume-rendered view
(arrowheads in e)
456 Insights Imaging (2011) 2:453–469myocardial wall thickness, wall thickness to chamber radius
ratio and regional functional parameters (e.g. systolic wall
thickening and wall motion), can be reliably assessed.
DCM-related pathological conditions such as thrombus
formation or valve dysfunction can be depicted by cine
MRI as well. Techniques such as myocardial tagging have
been shown to be very helpful in understanding the altered
myocardial deformation patterns in DCM patients [19, 20].
MRI can be used for myocardial tissue characterisation,
using T2-/T2*-weighted sequences and/or contrast-
enhanced MRI. These sequences may even replace endo-
myocardial biopsy in some diseases (e.g. iron deposition
cardiomyopathy). T2-weighted sequences allow increased
myocardial free water content to be depicted, which occurs
in the setting of acute myocardial infarction or in other
diseases characterised by inflammation, such as acute
myocarditis. Affected regions will appear bright compared
with the normal myocardium. In the case of diffuse
myocardial oedema, some authors recommend to measure
the difference in signal intensity between myocardium and
skeletal muscle (Fig. 5)[ 21]. T2*-weighted sequences are
of great value for the diagnosis of myocardial iron
deposition diseases, leading to a shortening of T2*
relaxation time (Fig. 6). This parameter can be used to
predict complications such as heart failure and arrhythmias
and can be used to initiate and monitor chelation therapy
[22, 23]. Compared with normal myocardium, in patholog-
ical myocardium the gadolinium contrast kinetics are
altered, secondary to changes in distribution volume and/
or wash-out of gadolinium. For the diagnosis of focal
myocardial disease, such as necrosis/fibrosis, contrast-
enhanced imaging using fast gradient-echo sequences with
a preparatory inversion pulse [the so-called “late gadolin-
ium enhancement” (LGE) or “delayed enhancement”
technique] have been shown to be of great value [24].
Although initially applied to depict myocardial necrosis/
fibrosis in the setting of acute or chronic myocardial
infarction, the LGE MRI technique allows several non-
ischaemic patterns of myocardial enhancement to be
described in a wide range of myocardial diseases [25]. A
weakness of the LGE MRI technique, however, is that it is
optimised for depicting focal myocardial pathological
conditions, and therefore it may fail to show diffusely
spread disease, such as diffuse myocardial fibrosis, found in
patients with DCM [26]. Comparing global myocardial
enhancement with skeletal muscle enhancement early after
gadolinium administration is of use to depict generalised
myocardial hyperaemia, which can be found in patients
with myocardial inflammation not only in the acute phase
but also in chronic forms of myocarditis (Fig. 5)[ 27, 28].
Besides, myocardial T1 mapping techniques are appealing
for the depiction of diffuse myocardial fibrosis, and
represent a valuable addition to the LGE MRI technique.
Shortening of the myocardial T1 relaxation time is related
to the amount of myocardial collagen deposition [26, 29,
30]. Performing fast gradient-echo sequences using multi-
ple increasing inversion times (e.g. 50–1,000 ms) before
and after contrast-medium administration at the blood/
myocardium equilibrium phase, allows the decay in
myocardial signal intensity to be measured, and T1 maps
to be generated with the use of curve fitting techniques
(Movie 2). Although this technique is promising, further
investigation is needed to test its robustness in assessing
patients in mainstream clinical practice. Finally, a free
Fig. 5 MRI approach for depiction of changes in global myocardial
tissue characteristics. Midventricular short-axis T2-weighted short
inversion-time inversion-recovery (STIR) fast spin-echo (left), T1-
weighted fast spin-echo before (middle) and at 4 min after adminis-
tration of 0.2 mmol of gadolinium DTPA/kg body weight (right).
Calculation of the ratio of the differences in signal intensity between
myocardial and skeletal muscle using T2-weighted STIR fast spin-
echo allow generalised myocardial oedema to be depicted (left), while
the changes in signal intensity early after contrast medium adminis-
tration allow myocardial hyperaemia to be visualised (right)
Insights Imaging (2011) 2:453–469 457bonus of the LGE MRI technique is that concomitant
cardiac disease, such as pericardial inflammation or
thrombus formation, can be accurately depicted as well
[31–33].
Even if MDCT is not yet considered as a first-line
imaging technique for the evaluation of LV performance
and volumes, it is important to mention that in patients
undergoing an MDCT examination for coronary artery
evaluation, reliable information about cardiac morphology
and function can be obtained without any additional
radiation exposure [34–37]. Although nowadays the pro-
spective trigger mode is preferable because of the signifi-
Fig. 6 Hereditary haemochromatosis in a 56-year-old man. T2*-weighted sequences show significantly decreased myocardial T2* (13 ms)
(normal value at 1.5 Tesla: 33.3±7.8 ms). The patient showed no evidence of systolic or diastolic dysfunction
458 Insights Imaging (2011) 2:453–469cant reduction in irradiation dose, reliable data regarding
ventricular volumes and function can be obtained using
retrospective electrocardiogram (ECG) gating. Several
papers reported good agreement among MDCT and
echocardiography, and MRI and invasive catheter ventricu-
lography, with good interobserver agreement [38–41].
Cardiac volumes and ventricular function
As the LV ejection fraction is the strongest prognostic
determinant in heart failure patients, while LV volume and
mass are independent predictors of mortality and morbidity,
a first primordial step in assessing DCM patients is the
reliable quantification of the severity of chamber dilatation
and dysfunction. Often stroke volumes are within normal
limits or only modestly decreased despite the severely
impaired ejection fraction. The LV enlargement may
furthermore dilate the mitral valve ring, dislocate the
papillary muscles, and impair leaflet coaption, thereby
causing mitral valve regurgitation and putting additional
load on the already diseased ventricle (Fig. 1). Except for
mildly dilated forms of DCM, the LV and/or RV show a
moderate to severe degree of dilatation with a severely
impaired ejection fraction (e.g. lower than 20%) (Figs. 1
and 3). The volumetric measurement of the ventricles is
usually performed in the cardiac short-axis plane (MRI) or
using reconstructed images in the cardiac short-axis plane
(MDCT). For MDCT evaluation of LV function, end-
diastole is usually identified as the image with the
maximum diameter (approximately at 85% of RR diame-
ter), while the minimum diameter (about 25% of RR)
corresponds to end-systole. Software has been developed to
semi-automatically determine ventricular volumes and
function, and myocardial mass.
In DCM patients, the atria may be enlarged as well, but
this is usually less pronounced than the ventricular
dilatation. Left atrial dilatation can be related to mitral
valve regurgitation and/or to increased LV filling pressure,
emphasising the need for assessment of diastolic (dys)
function in DCM patients. Phase-contrast (or velocity-
encoded) cine MRI is an accurate technique for quantifying
the severity of valve regurgitation and for providing
information on diastolic function. Although MDCT can
provide MR-equivalent high-quality morphological views
of the mitral valve, and even show valve motion, it provides
no or at most limited information regarding the severity of
regurgitation. However, the superb morphological visual-
isation of the mitral valve and subvalvular apparatus
provide a means of better characterising the mechanism(s)
of mitral valve regurgitation. Moreover, slow or turbulent
flow in dilated cavities facilitates thrombus formation. Both
MRI and MDCT can be regarded as excellent tools for
depicting this potentially harmful complication (Fig. 7).
Myocardial contractility
Myocardial contraction abnormalities are invariably present
in DCM patients, visible as hypokinetic to dyskinetic wall
motion, diminished to absent systolic wall thickening, and a
variable degree of ventricular dyssynchrony often with
abnormal systolic motion of the interventricular septum and
apical rocking (Movie 3). Cine MRI is without any doubt the
reference tool for assessing myocardial wall motion and
thickening patterns, and has potential in the assessment of
ventricular dyssynchrony. Regional abnormalities are usually
described using the 17-segment AHA approach.
Myocardial tissue characterisation
Accurate myocardial tissue characterisation is pivotal in
DCM patients. For example, as reported by Bello et al.
[42], the response to b-blockade therapy was significantly
better with functional improvement and reversed ventricular
remodelling in heart failure patients without evidence of
myocardial scarring by LGE MRI than those with myocar-
Fig. 7 Small thrombus in the LV
apex in a male patient with a
moderately dilated cardiomyopa-
thy. Vertical long-axis SSFP cine
MRI (left), contrast-enhanced
MRI early after contrast medium
administration using a long
inversion time (i.e. 550 ms)
(right). The thrombus is hardly
visible on cine MRI (left)b u ti s
well depicted as a hypointense
rounded nodular structure on the
contrast-enhanced image (right)
Insights Imaging (2011) 2:453–469 459dial scarring. A first aim is to exclude myocardial damage
due to CAD as the underlying cause of ventricular
dilatation and dysfunction [43–45]. The presence and
pattern of myocardial LGE provides crucial information
regarding the ischaemic or non-ischaemic origin. Ischaemic
LGE involves the subendocardium with a variable trans-
mural extension in a coronary artery perfusion territory
(Fig. 8). In non-CAD-related DCM, myocardial LGE
presents most commonly as a linear or patchy midwall
enhancement. It may involve the subepicardial part of the
myocardium and the right ventricle as well, and importantly
it does not respect a perfusion territory (Fig. 3) [44–46]. It
should be emphasised, however, that most DCM patients
present no myocardial LGE [45]. Finally, a small percent-
age of DCM patients show a CAD-like pattern of
enhancement, despite a lack of obstructive CAD on
coronary angiography. A likely hypothesis is that these
patients had concomitant CAD with recanalisation of the
occlusive coronary artery or had an embolic event.
Ventricular remodelling and dysfunction will be influenced
significantly by the extent of CAD-related myocardial
scarring. Although use of MDCT has been reported to
depict CAD-related myocardial scarring in chronic infarct
patients, currently this application is not routinely used
[47].
Although LGE MRI is able to depict subtle forms of
myocardial scarring (<1 g) [48], this sequence is of limited
value in depicting diffuse myocardial fibrosis, probably
explaining why most DCM patients in the study by
McCrohon et al. [45] showed normal LGE MRI. Recently,
substantial progress has been made with the development of
myocardial T1 mapping techniques. Diffuse collagen
deposition increases the extracellular space, causing an
increased interstitial accumulation of gadolinium at steady
state, thus reducing the myocardial T1 relaxation time [26,
29, 30, 49, 50]. Several groups have reported in DCM
patients a tight relation between the expansion in extracel-
lular space (reflecting myocardial fibrosis) and the impair-
ment in myocardial blood flow, ventricular dilatation and
ventricular dysfunction [29, 50–52].
It is believed that approximately 5-10% of patients with
acute myocarditis progress towards DCM and ultimately
will need cardiac transplantation [1, 53]. While the role of
MRI in the diagnosis of acute myocarditis is well
established, with recently published recommendations by
an expert committee (“Lake Louise Criteria”)[ 27], the role
of MRI in chronic myocarditis is less well defined, but is
probably important because patients with DCM secondary
to chronic myocarditis may show a favourable response to
immunomodulatory therapy. De Cobelli et al. [54] reported
in patients with biopsy-proven chronic myocarditis a
similar focal pattern of enhancement as in patients with
acute myocarditis in up to 70% of a group of patients with
chronic inflammation at endomyocardial biopsy. Moreover,
Fig. 8 Extensive transmural
anteroapical infarction in 46-
year-old man. LGE MRI in the
vertical long axis (a). End-
diastolic SSFP cine MRI in the
horizontal long-axis in the first
week (b), at 1 year (c), and at
5 years post-infarction (d). Note
the progressive increase in LV
end-diastolic volume with
thinning of the LV wall,
reflecting adverse ventricular
remodelling
460 Insights Imaging (2011) 2:453–469patients with persistent chronic myocarditis frequently
showed generalised myocardial oedema and increase in
global myocardial enhancement. On the other hand, focal
myocardial LGE, probably reflecting myocardial scarring,
had low sensitivity and specificity in depicting chronic
myocarditis [28, 55]. Finally, Mahrholdt et al. [53]
evaluated patients with acute myocarditis at the 3-month
follow-up and reported a significant reduction in the extent
of midwall/subepicardial focal myocardial enhancement
representing residual inflammation or fibrotic scarring.
Left ventricular non-compaction cardiomyopathy
In DCM patients, myocardial trabeculations, along the LV
free wall, often appear more prominent than in healthy
subjects [56]. The exact mechanism is unclear but may
represent a compensatory phenomenon. Differentiation
between DCM and left ventricular non-compaction cardio-
myopathy (LVNC) may be challenging, especially in mild
forms of LVNC (Fig. 9)[ 57, 58]. Nowadays recognised as
a distinct cardiomyopathy, LVNC is thought to be caused
by intrauterine arrest of the process of compaction of the
loosely interwoven meshwork of myocardial fibres [59,
60]. As a result, LVNC patients present with prominent
trabeculations, deep intertrabecular recesses and a thin
epicardial compacta. An alternative hypothesis suggests
that the prominent trabeculations represent an adaptive
mechanism to compensate for abnormally contracting
myocardium [61]. Most commonly, the apical and midven-
tricular part of the inferior and lateral LV wall are affected
(Fig. 10)[ 62]. Attempts to define diagnostic morphological
criteria for LVNC have been shown to be challenging,
mainly due to the lack of an easy-to-use parameter enabling
the differentiation of LVNC patients from normal subjects
or other disease entities [61–63]. In brief, criteria have been
defined taking into account the two-layered appearance of
the myocardial wall, the ratio of non-compacted to
compacted myocardium, the number of visible trabecula-
tions apically to the papillary muscles, and the presence of
deep intertrabecular spaces visualised on colour Doppler
imaging. In a recent study by Kohli and co-workers, it was
shown that these diagnostic criteria are likely too sensitive
with up to a quarter of heart failure patients and 8% of
control subjects fulfilling one or more criteria for LVNC
[64, 65]. On the other hand, other papers, including MRI
findings, suggest that the echocardiographic criteria might
be too strict, and that techniques such as MRI may enhance
detection of more subtle forms of LVNC [60, 66, 67]. The
superior spatial and contrast resolution of MRI makes this
technique appealing for the detection of LVNC. The
location and extent of the trabecular network, and the
Fig. 9 Dilated dysfunctional LV
in a 19-year-old woman. SSFP
cine MRI in the horizontal long
axis at end-diastole (a)a n de n d -
systole (b), and in the vertical
long-axis at end-diastole (c)a n d
end-systole (d). The LV end-
diastolic volume is 260 ml with
an ejection fraction of 11%. Note
an extreme thinning of the
myocardial wall, in particular of
the interventricular septum, and
the presence of thick pronounced
trabeculations in the LV apex.
Although MRI enables the
morphological abnormalities to
be depicted accurately, it remains
challenging in this patient to
differentiate between an LV
non-compaction cardiomyopathy
and a DCM with compensatory
trabecular hypertrophy
Insights Imaging (2011) 2:453–469 461thickness of the trabeculations and compacta can be well
visualised using a combination of cine MRI in different
cardiac imaging planes. In addition, these sequences allow
the impact of morphological abnormalities on regional and
global function to be assessed. LGE MRI may reveal
underlying myocardial disease such as replacement fibrosis
[68, 69]. In 2005, Petersen et al. [70] established MRI
criteria for the diagnosis of LVNC, similar to the above-
mentioned echocardiographic criteria. An NC/C ratio >2.3
in diastole distinguished LVNC from normals, athletes and
a series of cardiac diseases with a sensitivity and specificity
of 86 and 99% respectively. Jacquier et al. [71] proposed to
quantify the percentage of trabeculated LV myocardium,
and reported in normals 12±5% trabeculated myocardium
vs 32±10% in LVNC patients. Although promising, the
applicability of the above MRI criteria in daily clinical
practice needs further confirmation.
Myocardial viability assessment
Obstructive CAD may cause myocardial ischaemia and
dysfunction, and initiate compensatory ventricular remod-
elling with progressive dilatation, which ultimately may
lead to ischaemic heart failure (Fig. 8). The crucial question
to solve in these patients is whether percutaneous or
surgical coronary revascularisation will improve function
in the dysfunctional regions and ultimately improve patient
outcome [72]. As the myocardial substrate underlying the
dysfunction in the setting of CAD is heterogeneous,
including stunned, ischaemic, hibernating, necrotic and
scarred myocardium, the goal of myocardial viability
assessment is to determine the ischaemic substrate. It is
important to emphasise that different ischaemic substrates
can be present within the same coronary perfusion territory
[73, 74]. Only the viable substrates may recover function
following reperfusion. Even if there are not yet any
prospectively controlled studies on the effects of revascu-
larisation, there is a substantial amount of clinical evidence
that patients with reversible LV dysfunction may benefit
from a revascularisation procedure [75, 76].
The role of MDCT in these patients is mainly focused on
visualisation of coronary artery plaques, but no information
is provided regarding the viability of the myocardium
downstream of the coronary atherosclerotic plaque. MRI is
nowadays emerging as one of the preferential techniques
for characterising the ischaemic substrate and determining
myocardial viability. Three different approaches, or a
combination of approaches, can be used for MRI myocar-
dial viability assessment, i.e. end-diastolic wall thickness,
contractility reserve and scar imaging (Fig. 11). First,
measurement of end-diastolic wall thickness relies on the
premise that infarction with subsequent scarring leads to
wall thinning, and the magnitude of wall thinning is related
to the degree of infarct transmurality [77, 78]. A wall
thickness of 6 mm has been proposed as a cut-off to
differentiate between non-viable and viable segments. This
approach has excellent sensitivity (95%, range 94-100%),
but poor specificity (41%, range 19-53%) for predicting
functional recovery [76–79]. Patients may present “pre-
served” segmental wall thickness but not recover function
following revascularisation, which is probably caused by
the presence of subendocardial scarring in this segment. For
this reason, the use of the thickness of the non-enhanced
rim on LGE MRI may be superior to end-diastolic wall
thickness in predicting recovery [80]. Contractile reserve
assessment, using low-dose dobutamine stress MRI is the
second approach to assessing myocardial viability. Whereas
the contractility of normal viable myocardium increases
during dobutamine stress, the response of ischaemic,
dysfunctional myocardial segments depends on the myo-
cardial substrate (Fig. 12)[ 78, 81–83]. This approach has
good specificity (83%, range 70-95%) but moderate
sensitivity (74%, range 50-89%) [68–71]. The third
approach relies on the use of LGE MRI to depict the
presence and transmural extent of myocardial scarring.
Lack of myocardial LGE in dysfunctional myocardium is
indicative of viability, and these segments have a high
probability of functional recovery post-revascularisation.
On the other hand, the probability of functional recovery is
inversely related to the transmural extent of myocardial
LGE [84, 85]. Despite excellent sensitivity (95%, range 91–
99%), LGE MRI has low specificity (45%, range 37–54%).
In particular, for subendocardial infarcts, LGE MRI does
not provide information on whether the non-enhanced
epicardial rim contains normal, viable or jeopardised
myocardium [79]. In order to increase diagnostic accuracy,
an integrated MRI approach can be used. For instance,
Fig. 10 Typical example of LV non-compaction cardiomyopathy.
Four-chamber SSFP cine MR image at end-diastole. Note the presence
of an increased number of trabeculations along the LV lateral wall and
LV apex (arrowheads)
462 Insights Imaging (2011) 2:453–469adding low-dose dobutamine stress MRI in a second step
after LGE MRI may be helpful in determining the
myocardial substrate of the non-enhanced epicardial rim.
As mentioned above, determining the thickness of the non-
enhanced epicardial rim may provide additional value
regarding viability [80] with a cut-off value of 3 mm
yielding good diagnostic accuracy for the differentiation
between viable and non-viable segments.
Arrhythmogenic substrate
As sudden cardiac death due to ventricular arrhythmias may
be the first clinical manifestation of DCM, identification of
patients at risk who may benefit from implantable cardi-
overter defibrillator (ICD) implantation or from an ablation
procedure is of primordial importance. Several papers have
shown that non-ischaemic cardiomyopathy patients with
midwall myocardial LGE involving more than 25% of wall
thickness are at high risk at inducible ventricular tachycar-
dia and should be referred for definitive anti-arrhythmic
device therapy [86–89]. LGE MRI adds predictive value
especially in the DCM patients with a mildly to moderately
decreased ejection fraction, those with abnormal myocardi-
al enhancement having potential benefit from prophylactic
ICD placement [90]. In a recent study by Hombach et al.
[10] that included 141 DCM patients, midwall myocardial
LGE was not an independent prognostic factor, stressing
the need for large prospective studies on this topic [10].
Bogun et al. used LGE MRI to plan an appropriate mapping
and ablation strategy in a small group of DCM patients
[91]. The location of the scar (endocardial versus epicardi-
al) was an important factor in determining the optimal
approach to ablation. However, the success of catheter
ablation was low in patients with a scar located in the
midwall.
Fig. 11 Different MRI approaches to assessing myocardial viability.
Above in this figure is shown a short-axis slice through the left ventricle.
The black myocardium represents normal, viable myocardium while the
white myocardium represents chronic dysfunctional myocardium. Three
approaches or a combination of approaches can be used to determine the
myocardial substrate underlying the chronic dysfunction
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In patients with DCM, ventricular dilatation and replace-
ment fibrosis lead to a heterogeneous excitation spread
across the LV wall with a delay in intraventricular
conduction and a left bundle branch block morphology on
the ECG. Segmental wall motion analysis shows hypo-
kinesis to dyskinesis with a variable degree of dyssyn-
chrony [92, 93]. Ventricular dyssynchrony worsens systolic
performance, impedes ventricular filling, and causes para-
doxical septal motion during early systole. Cardiac resynch-
ronisation therapy (CRT) consists of the implantation of a
biventricular pacemaker in order to improve synchronicity
of myocardial contraction leading to improved ventricular
performance. In properly selected patients, CRT implanta-
tion is associated with improvement of symptoms and a
decrease in mortality and hospitalisation for heart failure.
However, up to 40% of CRT-treated patients show no
benefit from CRT, urging the need for better identification
of responders to CRT treatment.
MRI is a promising tool for identifying and selecting
patients eligible for CRT [93, 94]. MRI has the advantage
of integrating functional/dyssynchrony imaging with mor-
phological and tissue characterisation imaging. Novel MRI
techniques such as DENSE (displacement encoding with
stimulated echoes) and TVM (tissue velocity mapping) are
appealing for the quantification of the degree of dyssyn-
chrony throughout the LV. In addition, LGE MRI enables
the depiction of myocardial scar presence and extent. The
higher the scar burden, the lower the chance of CRT
response [95–97]. Moreover, as reported by Chalil et al.
[98] correct placement of CRT leads is crucial. Positioning
of the pacing lead in the scarred myocardium is followed by
a lack of CRT response. MRI is currently the best technique
for guiding the interventional cardiologist to correctly
position CRT leads. The lead should be placed in the
myocardium displaying the latest activation. On the other
hand, scar stimulation by pacing prevents correct impulse
transmission, and consequent inhibition of myocardial
contractility.
Another clinically relevant application for MRI and
MDCT is the identification of coronary venous anatomy
(Fig. 13). In particular, MDCT is a fast and very useful
technique in CRT therapy planning. As mentioned above,
CRT leads should be placed in the area of latest activation.
Once this has been identified, visualisation of the vein
tributary to that segment is mandatory. If there is no
evidence of a coronary vein on MDCT/MRI in these
segments, the transvenous approach is not recommended
because it would result in an erroneous lead placement. In
these cases, a surgical approach with epicardial lead
positioning is preferable. The efficacy of MDCT in
depicting coronary venous anatomy, including anatomical
variants, is excellent, showing good agreement with
anatomical studies and invasive venography [99, 100].
Coronary artery imaging
As previously mentioned, the ventricular dilatation associated
with systolic dysfunction can be due to DCM or secondary to
coronary artery disease. In the last two decades, coronary
artery imaging by MRI and MDCT has been extensively
studied as an alternative to invasive catheter angiography.
Fig. 12 Relation between myocardial substrate and functional
response during low-dose and high-dose dobutamine stress in an
animal model with chronic myocardial ischaemia. Whereas contrac-
tility gradually increases with increasing doses of dobutamine in
normal, remote myocardium, the response to stress is blunted in
chronic ischaemic but viable (no MI) segments. The response to
dobutamine stress in segments containing scarred myocardium
depends on the degree of transmurality, being worse in segments with
a scar transmurality of more than 50% (MI++) (Ming Wu, adapted
from [66])
464 Insights Imaging (2011) 2:453–469Despite high initial expectations, it has nowadays become
evident that MRI has a limited role in depicting coronary
artery plaques [101]. Supported by encouraging results of
several single-centre and multicentre trials, MDCT is now
considered a reliable method for the detection and, in
particular, for the exclusion of CAD [12, 102]. However, it
should be emphasised that MDCT still faces many chal-
lenges, in particular imaging of heavily calcified plaques and
stent imaging, although further improvement can be
expected with newer generation equipment [103].
Fig. 13 MDCT with volume-
rendered images (a) and MR
coronary angiography (b)
showing the heart and the
coronary artery and venous
system (arrowheads). Ao aorta,
D diagonal branch, LAD left
anterior descending coronary
artery, LCx left circumflex
coronary artery, LM left main
coronary artery, RCA right
coronary artery
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In the end, the role of an imaging method is to provide
accurate information for the clinician, to minimise the
degree of uncertainty in the diagnosis and patient manage-
ment, and to improve patient outcome. MRI is becoming
generally accepted as an important imaging technique in
patients with DCM offering the clinician not only accurate
information regarding the severity of ventricular dilatation
and dysfunction but also regarding myocardial tissue
composition, which is important in establishing the under-
lying cause, in predicting the risk of future events, and in
selecting eligible candidates for CRT. The fast and
continuous progress in MDCT technology has enabled
accurate information regarding coronary artery and venous
anatomy to be provided, but this technique has the potential
to offer a broader cardiac assessment, including tissue
characterisation and functional assessment.
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